Activation	O
of	O
mesenchymal	O
stem	O
cells	O
by	O
macrophages	O
promotes	O
tumor	B-DS
progression	O
through	O
immune	O
suppressive	O
effects	O

Cancer	B-DS
development	O
and	O
progression	O
is	O
linked	O
to	O
tumor	B-DS
-	O
associated	O
macrophages	O
(	O
TAMs	O
).	O

Distinct	O
TAMs	O
subsets	O
perform	O
either	O
protective	O
or	O
pathogenic	O
effects	O
in	O
cancer	B-DS
.	O

A	O
protective	O
role	O
in	O
carcinogenesis	O
has	O
been	O
described	O
for	O
M1	O
macrophages	O
,	O
which	O
activate	O
antitumor	O
mechanisms	O
.	O

By	O
comparison	O
,	O
TAMs	O
isolated	O
from	O
solid	O
and	O
metastatic	B-DS
tumors	I-DS
have	O
a	O
suppressive	O
M2	O
-	O
like	O
phenotype	O
,	O
which	O
could	O
support	O
multiple	O
aspects	O
of	O
tumor	B-DS
progression	O
.	O

Currently	O
,	O
it	O
has	O
not	O
been	O
clearly	O
understood	O
how	O
macrophages	O
in	O
tumor	B-DS
-	O
associated	O
stroma	O
could	O
be	O
hijacked	O
to	O
support	O
tumor	B-DS
growth	O
.	O

Mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
actively	O
interact	O
with	O
components	O
of	O
the	O
innate	O
immune	O
system	O
and	O
display	O
both	O
anti	O
-	O
inflammatory	O
and	O
pro	O
-	O
inflammatory	O
effects	O
.	O

Here	O
,	O
we	O
tested	O
whether	O
MSCs	O
could	O
favor	O
the	O
tumor	B-DS
to	O
escape	O
from	O
immunologic	O
surveillance	O
in	O
the	O
presence	O
of	O
M1	O
macrophages	O
.	O

We	O
found	O
that	O
MSCs	O
educated	O
by	O
M1	O
condition	O
medium	O
(	O
cMSCs	O
)	O
possessed	O
a	O
greatly	O
enhanced	O
ability	O
in	O
promoting	O
tumor	B-DS
growth	O
in	O
vivo	O
.	O

Examination	O
of	O
cytokines	B-GP
/	O
chemokines	B-GP
showed	O
that	O
the	O
cMSCs	O
acquired	O
a	O
regulatory	O
profile	O
,	O
which	O
expressed	O
high	O
levels	O
of	O
iNOS	B-GP
and	O
MCP1	B-GP
.	O

Consistent	O
with	O
an	O
elevated	O
MCP1	B-GP
expression	O
in	O
cMSCs	O
,	O
the	O
tumor	B-DS
-	O
promoting	O
effect	O
of	O
the	O
cMSCs	O
depended	O
on	O
MCP1	B-GP
mediated	O
macrophage	O
recruitment	O
to	O
tumor	B-DS
sites	O
.	O

Furthermore	O
,	O
IL	B-GP
-	I-GP
6	I-GP
secreted	O
by	O
the	O
cMSCs	O
could	O
polarize	O
infiltrated	O
TAMs	O
into	O
M2	O
-	O
like	O
macrophages	O
.	O

Therefore	O
,	O
when	O
macrophages	O
changed	O
into	O
M1	O
pro	O
-	O
inflammation	O
type	O
in	O
tumor	B-DS
microenvironment	O
,	O
the	O
MSCs	O
would	O
act	O
as	O
poor	O
sensors	O
and	O
switchers	O
to	O
accelerate	O
tumor	B-DS
growth	O
.	O

INTRODUCTION	O

Cancers	B-DS
develop	O
in	O
complex	O
tumor	B-DS
microenvironments	O
,	O
which	O
include	O
cells	O
such	O
as	O
endothelial	O
cells	O
,	O
immune	O
cells	O
,	O
tumor	B-DS
-	O
associated	O
macrophages	O
(	O
TAMs	O
),	O
and	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
[	O
1	O
].	O

Non	O
-	O
cancerous	O
stromal	O
cells	O
have	O
different	O
capabilities	O
to	O
induce	O
both	O
tumor	B-DS
-	O
promoting	O
and	O
tumor	B-DS
-	O
antagonizing	O
effects	O
[	O
2	O
].	O

The	O
contradictory	O
phenomenon	O
brings	O
us	O
a	O
problem	O
how	O
the	O
tumor	B-DS
-	O
associated	O
stroma	O
at	O
the	O
primary	O
sites	O
is	O
hijacked	O
to	O
support	O
tumor	B-DS
growth	O
.	O

The	O
key	O
mechanisms	O
may	O
focus	O
on	O
the	O
role	O
of	O
macrophages	O
,	O
immune	O
suppressor	O
cells	O
,	O
MSCs	O
,	O
the	O
vasculature	O
and	O
various	O
other	O
components	O
of	O
a	O
tumor	B-DS
-	O
supportive	O
microenvironment	O
.	O

Macrophages	O
are	O
resident	O
phagocytic	O
cells	O
in	O
tissues	O
,	O
which	O
play	O
important	O
roles	O
in	O
steady	O
-	O
state	O
tissue	O
homoeostasis	O
by	O
removing	O
cellular	O
debris	O
and	O
apoptotic	O
cells	O
.	O

Although	O
macrophages	O
are	O
classically	O
regarded	O
as	O
key	O
effector	O
cells	O
during	O
immune	O
defense	O
,	O
numerous	O
studies	O
have	O
demonstrated	O
a	O
clear	O
role	O
for	O
TAMs	O
in	O
supporting	O
various	O
aspects	O
of	O
tumor	B-DS
development	O
[	O
3	O
].	O

An	O
explanation	O
for	O
the	O
disparate	O
roles	O
of	O
macrophages	O
during	O
normal	O
tissue	O
homeostasis	O
and	O
carcinogenesis	O
lies	O
in	O
their	O
phenotype	O
[	O
4	O
].	O

At	O
the	O
extremes	O
of	O
their	O
phenotypic	O
continuum	O
,	O
macrophages	O
range	O
from	O
an	O
M1	O
to	O
M2	O
polarization	O
status	O
:	O
classically	O
activated	O
M1	O
macrophages	O
have	O
an	O
anti	O
-	O
tumorigenic	O
role	O
;	O
on	O
the	O
other	O
hand	O
,	O
alternatively	O
activated	O
M2	O
macrophages	O
promote	O
anti	O
-	O
inflammatory	O
responses	O
and	O
have	O
pro	O
-	O
tumorigenic	O
functions	O
.	O

Currently	O
,	O
we	O
do	O
not	O
fully	O
understand	O
how	O
macrophages	O
initially	O
switch	O
from	O
being	O
anti	O
-	O
tumor	B-DS
to	O
pro	O
-	O
tumorigenic	O
at	O
the	O
onset	O
of	O
disease	O
[	O
5	O
].	O

MSCs	O
are	O
one	O
of	O
the	O
major	O
components	O
of	O
the	O
tumor	B-DS
stroma	O
and	O
there	O
is	O
a	O
close	O
interaction	O
between	O
MSCs	O
and	O
the	O
immune	O
system	O
[	O
6	O
–	O
9	O
].	O

MSCs	O
have	O
been	O
shown	O
to	O
interact	O
with	O
a	O
variety	O
of	O
adaptive	O
immune	O
cells	O
including	O
T	O
cells	O
,	O
B	O
cells	O
and	O
dendritic	O
cells	O
[	O
10	O
].	O

Recently	O
,	O
it	O
was	O
demonstrated	O
that	O
the	O
MSCs	O
actively	O
interacted	O
with	O
components	O
of	O
the	O
innate	O
immune	O
system	O
and	O
that	O
through	O
these	O
interactions	O
,	O
they	O
displayed	O
both	O
anti	O
-	O
inflammatory	O
and	O
pro	O
-	O
inflammatory	O
effects	O
[	O
11	O
,	O
12	O
].	O

Within	O
the	O
innate	O
immune	O
system	O
,	O
it	O
was	O
well	O
established	O
that	O
macrophages	O
were	O
key	O
players	O
in	O
initiating	O
and	O
controlling	O
inflammation	O
and	O
the	O
MSCs	O
could	O
influence	O
macrophage	O
functions	O
[	O
13	O
,	O
14	O
].	O

In	O
a	O
tumor	B-DS
microenvironment	O
,	O
the	O
MSCs	O
are	O
often	O
constantly	O
exposed	O
to	O
immune	O
cells	O
and	O
inflammatory	O
cytokines	B-GP
/	O
chemokines	B-GP
.	O

They	O
may	O
have	O
acquired	O
functions	O
that	O
are	O
distinct	O
from	O
those	O
of	O
normal	O
MSCs	O
[	O
15	O
].	O

The	O
unique	O
features	O
may	O
play	O
a	O
role	O
in	O
regulating	O
the	O
tumor	B-DS
microenvironment	O
and	O
ultimately	O
affecting	O
tumor	B-DS
progression	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
MSCs	O
could	O
favor	O
a	O
tumor	B-DS
to	O
escape	O
from	O
immunologic	O
surveillance	O
in	O
an	O
environment	O
of	O
M1	O
macrophages	O
.	O

To	O
assess	O
the	O
possible	O
effects	O
of	O
M1	O
macrophages	O
on	O
the	O
MSCs	O
in	O
tumor	B-DS
growth	O
,	O
we	O
treated	O
MSCs	O
with	O
condition	O
medium	O
derived	O
from	O
M1	O
macrophages	O
(	O
cMSCs	O
),	O
characterized	O
by	O
their	O
tumor	B-DS
-	O
promoting	O
activity	O
and	O
phenotype	O
,	O
and	O
studied	O
the	O
mechanism	O
of	O
the	O
cMSCs	O
in	O
affecting	O
tumor	B-DS
growth	O
in	O
comparison	O
to	O
normal	O
MSCs	O
.	O

We	O
found	O
that	O
M1	O
macrophages	O
could	O
activate	O
the	O
MSCs	O
to	O
adopt	O
a	O
regulatory	O
phenotype	O
,	O
and	O
the	O
cMSCs	O
promoted	O
tumor	B-DS
growth	O
by	O
iNOS	B-GP
and	O
MCP1	B-GP
.	O

Therefore	O
,	O
this	O
study	O
revealed	O
that	O
the	O
MSCs	O
sensed	O
and	O
controlled	O
inflammation	O
to	O
promote	O
tumor	B-DS
growth	O
in	O
a	O
pro	O
-	O
inflammatory	O
environment	O
.	O

RESULTS	O

cMSCs	O
had	O
more	O
potential	O
than	O
untreated	O
-	O
MSCs	O
to	O
promote	O
tumor	B-DS
growth	O

Macrophage	O
cell	O
-	O
line	O
RAW264	O
.	O
7	O
cell	O
exposure	O
to	O
IFN	B-GP
-	I-GP
γ	I-GP
and	O
LPS	O
drive	O
M1	O
polarization	O
with	O
potentiated	O
cytotoxic	O
and	O
antitumoral	O
properties	O
.	O

To	O
confirm	O
the	O
M1	O
macrophage	O
phenotype	O
,	O
the	O
expression	O
of	O
iNOS	B-GP
(	O
M1	O
macrophage	O
marker	O
)	O
examined	O
by	O
a	O
FACS	O
analysis	O
clearly	O
increased	O
,	O
while	O
the	O
expression	O
of	O
CD11b	B-GP
(	O
macrophage	O
marker	O
)	O
remained	O
unchanged	O
(	O
Figure	O
S1A	O
).	O

Macrophage	O
M1	O
polarization	O
was	O
also	O
assessed	O
at	O
the	O
mRNA	O
level	O
using	O
real	O
-	O
time	O
PCR	O
by	O
measuring	O
the	O
expression	O
of	O
several	O
classical	O
M1	O
markers	O
:	O
TNFα	B-GP
,	O
IL	B-GP
-	I-GP
1β	I-GP
,	O
and	O
iNOS	B-GP
.	O

An	O
increased	O
IL	B-GP
-	I-GP
1β	I-GP
and	O
iNOS	B-GP
expression	O
profile	O
was	O
obtained	O
by	O
incubation	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
and	O
LPS	O
.	O

We	O
also	O
checked	O
the	O
expression	O
at	O
the	O
mRNA	O
level	O
of	O
several	O
M2	O
markers	O
(	O
IL	B-GP
-	I-GP
10	I-GP
,	O
Arg	B-GP
-	I-GP
1	I-GP
and	O
FIZZ	B-GP
-	I-GP
1	I-GP
)	O
in	O
M1	O
macrophages	O
,	O
but	O
in	O
our	O
conditions	O
,	O
we	O
observed	O
no	O
significant	O
expression	O
of	O
these	O
genes	O
.	O

In	O
addition	O
,	O
the	O
mRNA	O
abundance	O
of	O
signal	B-GP
regulatory	I-GP
protein	I-GP
-	I-GP
a	I-GP
(	O
SIRPα	B-GP
)	O
was	O
significantly	O
reduced	O
(	O
Figure	O
S1A	O
).	O

SIRPα	B-GP
is	O
a	O
membrane	B-GP
receptor	I-GP
expressed	O
by	O
macrophages	O
.	O

The	O
interactions	O
of	O
CD47	B-GP
-	O
SIRPα	B-GP
form	O
a	O
barrier	O
for	O
antibody	O
-	O
mediated	O
tumor	B-DS
cell	O
destruction	O
[	O
16	O
].	O

In	O
order	O
to	O
study	O
the	O
effects	O
of	O
M1	O
macrophages	O
on	O
cancer	B-DS
cell	O
response	O
in	O
vivo	O
,	O
prior	O
to	O
implantation	O
of	O
M1	O
macrophages	O
,	O
breast	B-DS
cancer	I-DS
models	O
with	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
FLUC	O
cells	O
were	O
set	O
up	O
.	O

Two	O
hours	O
after	O
M1	O
macrophages	O
had	O
been	O
injected	O
into	O
tumor	B-DS
sites	O
,	O
we	O
found	O
that	O
M1	O
macrophages	O
exhibited	O
radical	O
scavenging	O
potential	O
since	O
the	O
amount	O
of	O
tumor	B-DS
cells	O
remaining	O
was	O
10	O
%	O
compared	O
to	O
the	O
control	O
group	O
(	O
Figure	O
S1B	O
).	O

Therefore	O
,	O
incubation	O
of	O
macrophages	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
and	O
LPS	O
induces	O
their	O
polarization	O
into	O
M1	O
macrophages	O
,	O
and	O
M1	O
-	O
polarized	O
macrophages	O
have	O
strong	O
antitumor	O
activity	O
to	O
elicit	O
tumor	B-DS
disruption	O
.	O

To	O
investigate	O
the	O
characterization	O
of	O
the	O
cMSCs	O
,	O
MSCs	O
were	O
isolated	O
from	O
murine	B-OG
bone	O
marrow	O
.	O

The	O
morphology	O
of	O
the	O
mouse	B-OG
MSCs	O
displayed	O
a	O
homogenous	O
spindle	O
-	O
shaped	O
population	O
.	O

FACS	O
was	O
used	O
to	O
identify	O
the	O
surface	O
marker	O
expression	O
of	O
the	O
MSCs	O
.	O

High	O
expression	O
of	O
CD29	B-GP
,	O
CD73	B-GP
,	O
CD90	B-GP
and	O
CD105	B-GP
was	O
observed	O
,	O
but	O
CD34	B-GP
and	O
CD45	B-GP
were	O
down	O
-	O
regulated	O
(	O
data	O
not	O
shown	O
).	O

MSC	O
were	O
stimulated	O
by	O
the	O
medium	O
from	O
M1	O
macrophages	O
for	O
24	O
hours	O
to	O
achieve	O
the	O
cMSCs	O
.	O

To	O
determine	O
whether	O
the	O
cMSCs	O
could	O
promote	O
human	B-OG
tumor	B-DS
growth	O
,	O
we	O
injected	O
the	O
cMSCs	O
into	O
immune	O
deficient	O
mice	B-OG
with	O
human	B-OG
carcinoma	B-DS
cells	O
,	O
while	O
untreated	O
MSCs	O
were	O
used	O
as	O
controls	O
.	O

When	O
co	O
-	O
injected	O
with	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
FLUC	O
breast	B-DS
cancer	I-DS
cells	O
,	O
the	O
cMSCs	O
but	O
not	O
the	O
untreated	O
MSC	O
remarkably	O
increased	O
the	O
tumor	B-DS
-	O
initiating	O
ability	O
and	O
tumor	B-DS
growth	O
(	O
Figure	O
1A	O
,	O
1D	O
).	O

We	O
also	O
tested	O
the	O
effect	O
of	O
the	O
cMSCs	O
on	O
hepatocellular	O
HCC	O
-	O
LM3	O
-	O
FLUC	O
tumor	B-DS
growth	O
in	O
vivo	O
.	O

Similar	O
to	O
the	O
breast	B-DS
cancer	I-DS
model	O
,	O
the	O
cMSCs	O
caused	O
a	O
tumor	B-DS
-	O
promoting	O
effect	O
in	O
the	O
hepatocellular	B-DS
carcinoma	I-DS
model	O
as	O
compared	O
to	O
the	O
untreated	O
control	O
MSCs	O
group	O
(	O
Figure	O
1B	O
,	O
1E	O
).	O

The	O
cMSCs	O
also	O
led	O
to	O
a	O
significant	O
tumor	B-DS
promotion	O
of	O
malignant	B-DS
glioblastoma	I-DS
U87MG	O
-	O
FLUC	O
cells	O
(	O
Figure	O
1C	O
,	O
1F	O
).	O

Furthermore	O
,	O
after	O
the	O
cMSCs	O
were	O
co	O
-	O
injected	O
with	O
murine	B-OG
4T1	O
-	O
FLUC	O
cells	O
into	O
a	O
fat	O
pad	O
of	O
normal	O
mice	B-OG
,	O
the	O
cMSCs	O
were	O
more	O
effective	O
than	O
the	O
control	O
MSCs	O
in	O
promoting	O
tumor	B-DS
growth	O
(	O
data	O
not	O
shown	O
).	O

Therefore	O
,	O
the	O
cMSCs	O
displayed	O
greater	O
potential	O
to	O
promote	O
tumor	B-DS
growth	O
in	O
comparison	O
to	O
the	O
untreated	O
MSCs	O
.	O

cMSCs	O
promoted	O
tumor	B-DS
growth	O
in	O
vivo	O
to	O
a	O
greater	O
extent	O
than	O
untreated	O
-	O
MSCs	O

(	O
A	O
–	O
C	O
)	O
D	O
-	O
Luciferin	O
induced	O
bioluminescence	O
obtained	O
in	O
breast	O
(	O
A	O
),	O
liver	O
(	O
B	O
),	O
and	O
brain	O
(	O
C	O
)	O
cancer	B-DS
mice	B-OG
co	O
-	O
injected	O
with	O
cMSCs	O
,	O
MSCs	O
or	O
PBS	O
.	O

cMSCs	O
-	O
treated	O
mice	B-OG
displayed	O
a	O
significant	O
increase	O
in	O
tumor	B-DS
growth	O
.	O

(	O
D	O
–	O
F	O
)	O
Quantification	O
of	O
the	O
bioluminescent	O
signal	O
in	O
corresponding	O
breast	O
(	O
D	O
),	O
liver	O
(	O
E	O
),	O
and	O
brain	O
(	O
F	O
)	O
tumors	B-DS
after	O
treatments	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
MSCs	O
group	O
;	O
#	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
PBS	O
group	O
.	O

Stimulated	O
by	O
M1	O
medium	O
altering	O
the	O
cytokine	B-GP
/	O
chemokine	B-GP
expression	O
in	O
the	O
cMSCs	O

The	O
MSCs	O
affect	O
cancer	B-DS
progression	O
through	O
a	O
number	O
of	O
secreted	O
factors	O
triggering	O
activation	O
of	O
various	O
mechanisms	O
.	O

The	O
genetic	O
abnormalities	O
in	O
specific	O
genes	O
in	O
the	O
cMSCs	O
may	O
account	O
for	O
the	O
tumor	B-DS
-	O
promotion	O
activity	O
by	O
the	O
cMSCs	O
.	O

To	O
investigate	O
how	O
the	O
cMSCs	O
achieve	O
their	O
tumor	B-DS
-	O
promoting	O
effect	O
and	O
how	O
they	O
differ	O
from	O
untreated	O
MSCs	O
,	O
we	O
examined	O
the	O
gene	O
expression	O
profiling	O
of	O
the	O
cMSCs	O
.	O

Using	O
real	O
-	O
time	O
PCR	O
,	O
we	O
found	O
that	O
the	O
transcript	O
levels	O
of	O
iNOS	B-GP
,	O
MCP1	B-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
and	O
COX	B-GP
-	I-GP
2	I-GP
were	O
markedly	O
higher	O
in	O
the	O
cMSCs	O
than	O
in	O
untreated	O
MSCs	O
.	O

However	O
,	O
the	O
levels	O
of	O
CXCL9	B-GP
and	O
CXCL10	B-GP
were	O
lower	O
(	O
Figure	O
2A	O
).	O

A	O
previous	O
study	O
reported	O
a	O
new	O
MSCs	O
paradigm	O
by	O
specific	O
TLR	B-GP
-	O
priming	O
:	O
TLR4	B-GP
-	O
primed	O
MSC1	B-GP
and	O
TLR3	B-GP
-	O
primed	O
MSC2	B-GP
[	O
17	O
].	O

We	O
used	O
real	O
-	O
time	O
PCR	O
to	O
identify	O
additional	O
TLR	B-GP
genes	O
that	O
might	O
be	O
affected	O
,	O
and	O
found	O
that	O
TLR2	B-GP
,	O
TLR3	B-GP
,	O
and	O
TLR4	B-GP
were	O
induced	O
at	O
high	O
levels	O
in	O
the	O
cMSCs	O
compared	O
to	O
untreated	O
MSCs	O
.	O

Specifically	O
,	O
TLR3	B-GP
expression	O
was	O
increased	O
about	O
20	O
-	O
fold	O
after	O
M1	O
medium	O
treatment	O
(	O
Figure	O
2B	O
).	O

Furthermore	O
,	O
we	O
examined	O
the	O
chemotactic	O
potential	O
of	O
the	O
cMSCs	O
in	O
vitro	O
using	O
transwell	O
migration	O
assays	O
,	O
and	O
found	O
that	O
the	O
cMSCs	O
elicited	O
a	O
more	O
robust	O
migration	O
response	O
than	O
the	O
MSCs	O
(	O
Figure	O
2C	O
,	O
2D	O
).	O

Characterization	O
of	O
the	O
cMSCs	O

(	O
A	O
)	O
The	O
effects	O
of	O
the	O
M1	O
-	O
conditioned	O
medium	O
on	O
the	O
activation	O
of	O
various	O
gene	O
expressions	O
in	O
the	O
MSCs	O
were	O
assessed	O
by	O
using	O
real	O
-	O
time	O
PCR	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
;	O
**	O
P	O
<	O
0	O
.	O
01	O
.	O

(	O
B	O
)	O
The	O
expression	O
of	O
TLRs	B-GP
of	O
the	O
cMSCs	O
was	O
assessed	O
by	O
real	O
-	O
time	O
PCR	O
.	O
**	O
P	O
<	O
0	O
.	O
01	O
.	O

(	O
C	O
–	O
D	O
)	O
The	O
migration	O
ability	O
of	O
the	O
cMSCs	O
was	O
evaluated	O
.	O

(	O
C	O
)	O
Representative	O
images	O
of	O
the	O
MSCs	O
(	O
upper	O
)	O
and	O
cMSCs	O
(	O
lower	O
)	O
in	O
response	O
to	O
FBS	O
in	O
a	O
transwell	O
assay	O
.	O

Scale	O
bar	O
=	O
50	O
μm	O
.	O

(	O
D	O
)	O
Average	O
number	O
of	O
migrated	O
cells	O
in	O
a	O
transwell	O
migration	O
assay	O
.	O

Results	O
are	O
mean	O
values	O
±	O
SEM	O
of	O
five	O
different	O
fields	O
from	O
four	O
independent	O
experiments	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
versus	O
MSCs	O
.	O

(	O
E	O
–	O
F	O
)	O
Tumor	B-DS
-	O
associated	O
leukocytes	O
differ	O
among	O
the	O
cMSCs	O
and	O
MSCs	O
treated	O
groups	O
.	O

(	O
E	O
)	O
Immunohistochemical	O
staining	O
for	O
CD45	B-GP
(	O
red	O
)	O
and	O
DAPI	O
(	O
blue	O
)	O
in	O
4T1	O
-	O
FLUC	O
breast	B-DS
tumors	I-DS
14	O
days	O
after	O
co	O
-	O
injection	O
.	O

Scale	O
bars	O
=	O
50	O
μm	O
.	O

(	O
F	O
)	O
A	O
larger	O
number	O
of	O
CD45	B-GP
positive	O
bone	O
marrow	O
cells	O
were	O
stained	O
in	O
the	O
cMSCs	O
implantation	O
group	O
than	O
in	O
the	O
MSCs	O
and	O
the	O
PBS	O
injection	O
groups	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
MSCs	O
group	O
.	O

Abbreviations	O
:	O
HPF	O
,	O
high	O
-	O
power	O
field	O
.	O

Cancers	B-DS
develop	O
in	O
a	O
complex	O
tissue	O
environment	O
which	O
usually	O
contains	O
bone	O
marrow	O
derived	O
cells	O
.	O

We	O
employed	O
CD45	B-GP
+	O
to	O
identify	O
tumor	B-DS
-	O
associated	O
bone	O
marrow	O
cells	O
14	O
days	O
after	O
co	O
-	O
injection	O
with	O
4T1	O
-	O
FLUC	O
cells	O
and	O
cMSCs	O
or	O
untreated	O
MSCs	O
,	O
and	O
found	O
that	O
there	O
was	O
a	O
great	O
expansion	O
of	O
the	O
populations	O
of	O
CD45	B-GP
+	O
cells	O
in	O
tumors	B-DS
,	O
an	O
effect	O
that	O
was	O
dramatically	O
greater	O
with	O
the	O
cMSCs	O
than	O
untreated	O
MSCs	O
(	O
Figure	O
2E	O
,	O
2F	O
).	O

These	O
data	O
suggested	O
that	O
the	O
cMSCs	O
were	O
more	O
effective	O
than	O
the	O
untreated	O
MSCs	O
in	O
recruiting	O
CD45	B-GP
+	O
cells	O
to	O
tumor	B-DS
sites	O
.	O

In	O
view	O
of	O
the	O
immunosuppressive	O
ability	O
of	O
the	O
MSCs	O
,	O
we	O
examined	O
whether	O
cMSCs	O
have	O
immunosuppressive	O
function	O
.	O

The	O
splenocytes	O
were	O
activated	O
with	O
ConA	B-GP
followed	O
by	O
expansion	O
with	O
IL	B-GP
-	I-GP
2	I-GP
for	O
72	O
hours	O
.	O

We	O
co	O
-	O
cultured	O
the	O
activated	O
splenocytes	O
with	O
cMSCs	O
or	O
untreated	O
MSCs	O
.	O

The	O
results	O
showed	O
that	O
although	O
the	O
MSCs	O
could	O
not	O
inhibit	O
the	O
proliferation	O
of	O
splenocytes	O
,	O
the	O
inhibitory	O
effects	O
of	O
the	O
cMSCs	O
on	O
splenocytes	O
proliferation	O
were	O
significantly	O
increased	O
(	O
Figure	O
S2	O
).	O

cMSCs	O
exert	O
tumor	B-DS
promotion	O
of	O
the	O
required	O
iNOS	B-GP

High	O
concentrations	O
of	O
nitric	O
oxide	O
are	O
known	O
to	O
inhibit	O
immune	O
responses	O
to	O
promote	O
tumor	B-DS
growth	O
[	O
18	O
].	O

As	O
shown	O
above	O
,	O
iNOS	B-GP
mRNA	O
was	O
up	O
-	O
regulated	O
significantly	O
in	O
the	O
cMSCs	O
(	O
Figure	O
2A	O
).	O

To	O
investigate	O
the	O
role	O
of	O
nitric	O
oxide	O
,	O
its	O
production	O
was	O
shut	O
down	O
using	O
siRNA	O
to	O
inhibit	O
the	O
expression	O
of	O
iNOS	B-GP
.	O

RT	O
-	O
PCR	O
and	O
real	O
-	O
time	O
PCR	O
were	O
performed	O
to	O
assess	O
the	O
expression	O
of	O
iNOS	B-GP
in	O
cMSCs	O
to	O
further	O
confirm	O
the	O
transfection	O
efficiency	O
of	O
iNOS	B-GP
siRNA	O
.	O

iNOS	B-GP
expression	O
was	O
markedly	O
decreased	O
in	O
the	O
cMSCs	O
treated	O
by	O
iNOS	B-GP
siRNA	O
but	O
not	O
in	O
the	O
cMSCs	O
treated	O
by	O
control	O
-	O
siRNA	O
(	O
Figure	O
3A	O
),	O
which	O
showed	O
more	O
than	O
an	O
80	O
%	O
inhibitory	O
efficiency	O
rate	O
(	O
Figure	O
3B	O
).	O

Moreover	O
,	O
in	O
mixed	O
co	O
-	O
cultures	O
of	O
splenocytes	O
and	O
cMSCs	O
pre	O
-	O
treated	O
with	O
iNOS	B-GP
siRNA	O
or	O
iNOS	B-GP
inhibitor	O
1400	O
W	O
,	O
splenocyte	O
proliferation	O
was	O
restored	O
to	O
a	O
normal	O
level	O
(	O
Figure	O
S2	O
).	O

The	O
results	O
strongly	O
suggested	O
that	O
nitric	O
oxide	O
produced	O
by	O
the	O
cMSCs	O
mediated	O
the	O
suppression	O
of	O
splenocytes	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
that	O
the	O
4T1	O
tumor	B-DS
-	O
promoting	O
ability	O
of	O
the	O
cMSCs	O
was	O
dependent	O
upon	O
the	O
expression	O
of	O
iNOS	B-GP
(	O
Figure	O
3C	O
–	O
3D	O
).	O

Therefore	O
,	O
these	O
data	O
supported	O
that	O
immunosuppression	O
mediated	O
by	O
the	O
cMSCs	O
via	O
nitric	O
oxide	O
play	O
an	O
important	O
role	O
in	O
favoring	O
tumor	B-DS
cells	O
growth	O
.	O

The	O
growth	O
of	O
the	O
tumor	B-DS
favored	O
by	O
the	O
cMSCs	O
in	O
vivo	O
can	O
be	O
inhibited	O
by	O
iNOS	B-GP
siRNA	O

To	O
determine	O
the	O
effect	O
of	O
iNOS	B-GP
in	O
the	O
cMSCs	O
,	O
the	O
cMSCs	O
were	O
transfected	O
with	O
iNOS	B-GP
siRNA	O
or	O
control	O
siRNA	O
.	O

Mice	B-OG
were	O
divided	O
into	O
the	O
si	O
-	O
iNOS	B-GP
/	O
cMSCs	O
group	O
and	O
si	O
-	O
control	O
/	O
cMSCs	O
group	O
.	O

(	O
A	O
)	O
RT	O
-	O
PCR	O
showed	O
that	O
the	O
expression	O
of	O
iNOS	B-GP
was	O
decreased	O
in	O
the	O
cMSCs	O
in	O
which	O
transfections	O
of	O
iNOS	B-GP
siRNA	O
were	O
performed	O
with	O
a	O
Lipofectamine	O
.	O

(	O
B	O
)	O
Real	O
-	O
time	O
PCR	O
showed	O
that	O
the	O
inhibitory	O
efficiency	O
was	O
more	O
than	O
80	O
%	O
compared	O
with	O
the	O
control	O
siRNA	O
in	O
the	O
cMSCs	O
.	O

(	O
C	O
)	O
cMSCs	O
transfected	O
by	O
iNOS	B-GP
siRNA	O
did	O
not	O
support	O
4T1	O
-	O
FLUC	O
tumor	B-DS
cell	O
growth	O
.	O

(	O
D	O
)	O
Quantification	O
of	O
the	O
bioluminescent	O
signal	O
(	O
C	O
)	O
in	O
tumors	B-DS
after	O
treatments	O
.	O

MCP1	B-GP
-	O
mediated	O
macrophage	O
trafficking	O
is	O
critical	O
for	O
the	O
tumor	B-DS
-	O
promoting	O
effects	O
of	O
the	O
cMSCs	O

As	O
shown	O
above	O
,	O
the	O
cMSCs	O
were	O
more	O
effective	O
than	O
untreated	O
MSCs	O
in	O
recruiting	O
CD45	B-GP
+	O
cells	O
at	O
tumor	B-DS
sites	O
(	O
Figure	O
2E	O
),	O
which	O
may	O
include	O
monocytes	O
/	O
macrophages	O
,	O
B	O
cells	O
and	O
T	O
cells	O
.	O

Monocytes	O
/	O
macrophages	O
are	O
essential	O
for	O
the	O
tumor	B-DS
-	O
promoting	O
effect	O
of	O
MSCs	O
isolated	O
from	O
tumor	B-DS
sites	O
[	O
14	O
].	O

To	O
determine	O
whether	O
monocytes	O
/	O
macrophages	O
mediated	O
the	O
tumor	B-DS
-	O
promoting	O
effect	O
of	O
the	O
cMSCs	O
,	O
we	O
depleted	O
systemic	O
monocytes	O
/	O
macrophages	O
with	O
clodronate	O
liposomes	O
(	O
Clo	O
-	O
Lip	O
)	O
followed	O
by	O
injecting	O
mixtures	O
of	O
cMSCs	O
or	O
MSCs	O
with	O
4T1	O
tumor	B-DS
cells	O
into	O
mice	B-OG
14	O
days	O
after	O
transplantation	O
which	O
detected	O
the	O
tumor	B-DS
growth	O
by	O
BLI	O
.	O

We	O
found	O
that	O
depletion	O
of	O
monocytes	O
/	O
macrophages	O
in	O
our	O
system	O
had	O
an	O
effect	O
on	O
cMSCs	O
-	O
promoted	O
tumor	B-DS
growth	O
(	O
Figure	O
4A	O
),	O
indicating	O
that	O
monocytes	O
/	O
macrophages	O
are	O
indispensable	O
for	O
tumor	B-DS
growth	O
enhancement	O
induced	O
by	O
the	O
cMSCs	O
.	O

Tumor	B-DS
-	O
promoting	O
effect	O
of	O
the	O
cMSCs	O
relied	O
on	O
the	O
MCP1	B-GP
to	O
recruit	O
TAMs	O

(	O
A	O
)	O
Ablation	O
of	O
monocytes	O
/	O
macrophages	O
by	O
clodronate	O
liposomes	O
abolished	O
the	O
tumor	B-DS
-	O
promoting	O
activity	O
of	O
the	O
cMSCs	O
.	O

(	O
B	O
–	O
D	O
)	O
cMSCs	O
were	O
transfected	O
with	O
MCP1	B-GP
siRNA	O
.	O

Impact	O
of	O
MCP1	B-GP
deficiency	O
on	O
cMSCs	O
tumor	B-DS
promoting	O
effects	O
was	O
detected	O
.	O

Animals	B-OG
were	O
divided	O
into	O
the	O
si	O
-	O
MCP1	B-GP
/	O
cMSCs	O
group	O
and	O
si	O
-	O
control	O
/	O
cMSCs	O
group	O
.	O

(	O
B	O
)	O
Real	O
-	O
time	O
PCR	O
showed	O
that	O
the	O
expression	O
of	O
MCP1	B-GP
was	O
decreased	O
in	O
the	O
MSCs	O
in	O
which	O
transfections	O
of	O
MCP1	B-GP
siRNA	O
were	O
performed	O
with	O
a	O
Lipofectamine	O
.	O

(	O
C	O
)	O
The	O
in	O
vivo	O
growth	O
of	O
the	O
tumor	B-DS
favored	O
by	O
the	O
cMSCs	O
could	O
be	O
inhibited	O
by	O
MCP1	B-GP
siRNA	O
.	O

4T1	O
-	O
FLUC	O
tumor	B-DS
cell	O
growth	O
was	O
detected	O
by	O
BLI	O
after	O
establishing	O
the	O
breast	B-DS
carcinoma	I-DS
model	O
.	O

(	O
D	O
)	O
Representative	O
flow	O
cytometry	O
data	O
show	O
the	O
frequency	O
of	O
CD206	B-GP
macrophages	O
from	O
the	O
tumor	B-DS
and	O
peripheral	O
blood	O
of	O
4T1	O
bearing	O
control	O
mice	B-OG
.	O

MCP	B-GP
-	I-GP
1	I-GP
is	O
the	O
CCR2	B-GP
ligand	O
.	O

The	O
chemokine	B-GP
receptor	I-GP
CCR2	B-GP
is	O
known	O
to	O
be	O
expressed	O
on	O
monocytes	O
/	O
macrophages	O
.	O

Most	O
notably	O
,	O
MCP1	B-GP
,	O
the	O
major	O
chemokine	B-GP
for	O
macrophage	O
trafficking	O
,	O
was	O
expressed	O
at	O
a	O
high	O
level	O
by	O
the	O
cMSCs	O
,	O
but	O
not	O
by	O
the	O
untreated	O
MSCs	O
(	O
Figure	O
2A	O
),	O
suggesting	O
that	O
cMSCs	O
-	O
produced	O
MCP1	B-GP
may	O
play	O
an	O
important	O
role	O
in	O
cMSCs	O
-	O
promoted	O
tumor	B-DS
growth	O
.	O

To	O
examine	O
this	O
possibility	O
,	O
we	O
performed	O
MCP1	B-GP
knock	O
down	O
in	O
the	O
cMSCs	O
using	O
siRNA	O
.	O

We	O
found	O
that	O
siRNA	O
targeting	O
MCP1	B-GP
was	O
capable	O
of	O
inhibiting	O
MCP1	B-GP
in	O
the	O
cMSCs	O
(	O
Figure	O
4B	O
).	O

To	O
establish	O
the	O
role	O
of	O
cMSCs	O
-	O
expressed	O
MCP1	B-GP
in	O
tumor	B-DS
growth	O
promotion	O
and	O
macrophage	O
infiltration	O
in	O
vivo	O
,	O
we	O
co	O
-	O
transplanted	O
MCP1	B-GP
siRNA	O
treated	O
cMSCs	O
and	O
4T1	O
-	O
FLUC	O
tumor	B-DS
cells	O
into	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
.	O

We	O
found	O
that	O
the	O
tumor	B-DS
promoting	O
activity	O
of	O
the	O
cMSCs	O
was	O
largely	O
MCP1	B-GP
dependent	O
since	O
it	O
was	O
significantly	O
blocked	O
by	O
adding	O
MCP1	B-GP
siRNA	O
(	O
Figure	O
4C	O
).	O

MCP1	B-GP
could	O
induce	O
emigration	O
of	O
macrophages	O
from	O
the	O
bone	O
marrow	O
to	O
the	O
periphery	O
.	O

Furthermore	O
,	O
the	O
infiltrated	O
CD206	B-GP
positive	O
macrophages	O
in	O
the	O
blood	O
and	O
tumor	B-DS
sites	O
in	O
mice	B-OG
who	O
were	O
administered	O
cMSCs	O
and	O
were	O
treated	O
by	O
MCP1	B-GP
siRNA	O
or	O
control	O
siRNA	O
were	O
examined	O
by	O
flow	O
cytometry	O
.	O

We	O
found	O
that	O
an	O
MCP1	B-GP
deficiency	O
led	O
to	O
a	O
significant	O
reduction	O
in	O
CD206	B-GP
positive	O
macrophages	O
in	O
both	O
tumor	B-DS
tissues	O
and	O
peripheral	O
blood	O
(	O
Figure	O
4D	O
),	O
indicating	O
that	O
MCP1	B-GP
is	O
critical	O
for	O
trafficking	O
CD206	B-GP
+	O
macrophages	O
.	O

Altogether	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
cMSCs	O
probably	O
exert	O
their	O
tumor	B-DS
-	O
promoting	O
effect	O
by	O
recruiting	O
macrophages	O
to	O
tumor	B-DS
sites	O
through	O
the	O
production	O
of	O
MCP1	B-GP
.	O

cMSCs	O
convert	O
macrophages	O
into	O
M2	O
-	O
like	O
cells	O
to	O
promote	O
tumor	B-DS
growth	O

Macrophages	O
recruited	O
by	O
MCP1	B-GP
may	O
polarize	O
into	O
an	O
M1	O
or	O
M2	O
subset	O
in	O
a	O
tumor	B-DS
microenvironment	O
.	O

An	O
M2	O
polarized	O
population	O
promotes	O
tumor	B-DS
progression	O
.	O

To	O
examine	O
whether	O
the	O
cMSCs	O
remodel	O
the	O
phenotype	O
of	O
TAM	O
,	O
macrophages	O
and	O
cMSCs	O
were	O
co	O
-	O
incubated	O
in	O
a	O
transwell	O
for	O
24	O
hours	O
.	O

When	O
macrophages	O
were	O
further	O
examined	O
for	O
their	O
M1	O
/	O
M2	O
gene	O
expression	O
profile	O
by	O
real	O
-	O
time	O
PCR	O
,	O
we	O
found	O
that	O
macrophages	O
co	O
-	O
cultured	O
with	O
cMSCs	O
expressed	O
high	O
levels	O
of	O
FIZZ	B-GP
-	I-GP
1	I-GP
,	O
MCP1	B-GP
and	O
SIRPα	B-GP
(	O
Figure	O
5A	O
),	O
comprising	O
an	O
M2	O
-	O
preferential	O
gene	O
signature	O
in	O
comparison	O
to	O
control	O
macrophages	O
.	O

Interestingly	O
,	O
these	O
cMSCs	O
-	O
educated	O
macrophages	O
differed	O
slightly	O
from	O
the	O
traditional	O
M2	O
type	O
,	O
since	O
they	O
expressed	O
a	O
low	O
level	O
of	O
Arg	B-GP
-	I-GP
1	I-GP
.	O

Meanwhile	O
,	O
FACS	O
analysis	O
showed	O
that	O
the	O
increase	O
in	O
the	O
frequency	O
of	O
CD206	B-GP
+	O
cells	O
caused	O
by	O
the	O
cMSCs	O
was	O
detected	O
(	O
Figure	O
5D	O
).	O

The	O
results	O
suggested	O
that	O
the	O
cMSCs	O
generated	O
macrophages	O
with	O
a	O
similar	O
M2	O
phenotype	O
.	O

Moreover	O
,	O
to	O
determine	O
whether	O
M2	O
-	O
like	O
macrophages	O
treated	O
by	O
cMSCs	O
stimulate	O
the	O
growth	O
of	O
mammary	B-DS
cancer	I-DS
cells	O
in	O
vivo	O
,	O
we	O
injected	O
4T1	O
-	O
FLUC	O
cells	O
into	O
the	O
mammary	O
fat	O
pads	O
of	O
mice	B-OG
either	O
alone	O
or	O
coupled	O
with	O
M2	O
-	O
like	O
macrophages	O
.	O

The	O
accumulation	O
of	O
4T1	O
-	O
FLUC	O
cancer	B-DS
cells	O
in	O
the	O
mammary	O
fat	O
pads	O
was	O
increased	O
significantly	O
and	O
observed	O
by	O
BLI	O
and	O
bioluminescence	O
tomography	O
(	O
BLT	O
)	O
at	O
14	O
days	O
after	O
the	O
inoculation	O
as	O
compared	O
with	O
4T1	O
-	O
FLUC	O
cells	O
alone	O
(	O
Figure	O
5B	O
,	O
Movies	O
S1	O
and	O
S2	O
).	O

The	O
cMSCs	O
promoted	O
the	O
polarization	O
of	O
TAMs	O
into	O
M2	O
-	O
like	O
cells	O
through	O
IL	B-GP
-	I-GP
6	I-GP

(	O
A	O
)	O
Real	O
-	O
time	O
PCR	O
showed	O
that	O
the	O
cMSCs	O
educated	O
macrophages	O
increased	O
the	O
expression	O
of	O
FIZZ	B-GP
-	I-GP
1	I-GP
,	O
MCP1	B-GP
and	O
SIRPα	B-GP
compared	O
to	O
untreated	O
macrophages	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
;	O
**	O
P	O
<	O
0	O
.	O
01	O
.	O

(	O
B	O
)	O
The	O
growth	O
of	O
the	O
tumor	B-DS
was	O
favored	O
by	O
macrophages	O
stimulated	O
by	O
the	O
cMSCs	O
for	O
in	O
vivo	O
studies	O
.	O

(	O
C	O
–	O
D	O
)	O
Blocking	O
IL	B-GP
-	I-GP
6	I-GP
inhibited	O
cMSCs	O
-	O
mediated	O
induction	O
of	O
M2	O
-	O
like	O
macrophages	O
.	O

(	O
C	O
)	O
The	O
effects	O
of	O
IL	B-GP
-	I-GP
6	I-GP
and	O
COX	B-GP
-	I-GP
2	I-GP
antibody	O
on	O
the	O
activation	O
of	O
various	O
gene	O
expressions	O
in	O
the	O
cMSCs	O
were	O
assessed	O
by	O
using	O
real	O
-	O
time	O
PCR	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
.	O

(	O
D	O
)	O
Characterization	O
of	O
the	O
cMSCs	O
educated	O
macrophages	O
treated	O
or	O
untreated	O
by	O
IL	B-GP
-	I-GP
6	I-GP
antibody	O
.	O

Previous	O
findings	O
showed	O
that	O
secretory	O
factors	O
play	O
an	O
essential	O
role	O
in	O
MSCs	O
induced	O
polarization	O
of	O
M2	O
macrophages	O
[	O
11	O
].	O

In	O
this	O
study	O
,	O
IL	B-GP
-	I-GP
6	I-GP
and	O
COX	B-GP
-	I-GP
2	I-GP
were	O
expressed	O
at	O
higher	O
levels	O
in	O
the	O
cMSCs	O
than	O
MSCs	O
,	O
thus	O
we	O
explored	O
whether	O
these	O
secretory	O
factors	O
contributed	O
to	O
the	O
polarization	O
of	O
TAM	O
toward	O
an	O
M2	O
-	O
like	O
phenotype	O
.	O

Hence	O
,	O
macrophages	O
were	O
co	O
-	O
cultured	O
with	O
cMSCs	O
in	O
transwells	O
in	O
the	O
presence	O
specific	O
neutralizing	O
antibodies	O
for	O
IL	B-GP
-	I-GP
6	I-GP
and	O
COX	B-GP
-	I-GP
2	I-GP
for	O
24	O
hours	O
,	O
and	O
M2	O
macrophage	O
characteristics	O
were	O
determined	O
by	O
real	O
-	O
time	O
PCR	O
and	O
flow	O
cytometry	O
.	O

We	O
showed	O
that	O
the	O
addition	O
of	O
neutralizing	O
antibodies	O
specific	O
for	O
IL	B-GP
-	I-GP
6	I-GP
significantly	O
decreased	O
the	O
mRNA	O
expression	O
of	O
FIZZ	B-GP
-	I-GP
1	I-GP
,	O
MCP1	B-GP
,	O
SIRPα	B-GP
,	O
and	O
reduced	O
the	O
percentage	O
of	O
CD206	B-GP
positive	O
cells	O
,	O
as	O
compared	O
with	O
the	O
co	O
-	O
culture	O
control	O
treated	O
with	O
nonspecific	O
antibodies	O
(	O
Figure	O
5C	O
,	O
5D	O
).	O

Therefore	O
,	O
these	O
results	O
suggested	O
that	O
IL	B-GP
-	I-GP
6	I-GP
contributed	O
to	O
the	O
induction	O
of	O
M2	O
-	O
like	O
macrophages	O
mediated	O
by	O
co	O
-	O
culturing	O
with	O
cMSCs	O
.	O

DISCUSSION	O

The	O
inflammatory	O
response	O
can	O
promote	O
carcinogenesis	O
;	O
one	O
of	O
the	O
major	O
challenges	O
in	O
understanding	O
the	O
connection	O
between	O
inflammation	O
and	O
cancer	B-DS
is	O
to	O
identify	O
the	O
triggering	O
events	O
that	O
lead	O
to	O
the	O
inflammatory	O
responses	O
which	O
can	O
promote	O
tumorigenesis	O
.	O

Our	O
findings	O
demonstrated	O
an	O
event	O
of	O
cancer	B-DS
development	O
induced	O
by	O
inflammation	O
:	O
when	O
the	O
microenvironment	O
became	O
M1	O
pro	O
-	O
inflammatory	O
,	O
the	O
MSCs	O
acquired	O
a	O
regulatory	O
phenotype	O
and	O
promoted	O
tumor	B-DS
growth	O
.	O

The	O
tumor	B-DS
-	O
promoting	O
abilities	O
required	O
iNOS	B-GP
and	O
TAMs	O
;	O
TAMs	O
were	O
recruited	O
by	O
MCP1	B-GP
and	O
further	O
polarized	O
into	O
an	O
M2	O
-	O
like	O
phenotype	O
to	O
affect	O
tumorigenesis	O
.	O

We	O
use	O
Figure	O
6	O
to	O
describe	O
this	O
effect	O
.	O

These	O
results	O
thus	O
establish	O
a	O
mechanistic	O
link	O
between	O
the	O
M1	O
macrophage	O
and	O
tumor	B-DS
cells	O
via	O
MSCs	O
.	O

Proposed	O
model	O
depicted	O
the	O
interaction	O
between	O
macrophages	O
and	O
the	O
MSCs	O
in	O
promoting	O
tumor	B-DS
growth	O

M1	O
macrophages	O
could	O
activate	O
the	O
MSCs	O
to	O
adopt	O
a	O
regulatory	O
phenotype	O
,	O
and	O
the	O
cMSCs	O
promoted	O
tumor	B-DS
growth	O
by	O
iNOS	B-GP
,	O
MCP1	B-GP
and	O
induced	O
macrophages	O
toward	O
M2	O
-	O
like	O
macrophages	O
.	O

The	O
tumor	B-DS
microenvironment	O
is	O
a	O
complex	O
cellular	O
,	O
molecular	O
network	O
.	O

In	O
this	O
network	O
,	O
one	O
kind	O
of	O
cell	O
may	O
be	O
subjected	O
to	O
influences	O
from	O
various	O
stimuli	O
.	O

In	O
our	O
experiments	O
,	O
the	O
cMSCs	O
could	O
become	O
a	O
potent	O
immune	O
-	O
regulatory	O
component	O
.	O

A	O
previous	O
study	O
found	O
that	O
the	O
concomitant	O
presence	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
and	O
IFN	B-GP
-	I-GP
γ	I-GP
could	O
induce	O
the	O
immunosuppressive	O
functions	O
of	O
the	O
MSCs	O
,	O
as	O
these	O
cytokine	O
combinations	O
provoke	O
the	O
expression	O
of	O
high	O
levels	O
of	O
CXCL9	B-GP
,	O
CXCL10	B-GP
and	O
iNOS	B-GP
[	O
18	O
].	O

In	O
our	O
experimental	O
setting	O
,	O
CXCL9	B-GP
and	O
CXCL10	B-GP
were	O
expressed	O
at	O
low	O
levels	O
in	O
the	O
cMSCs	O
.	O

These	O
differences	O
may	O
suggest	O
that	O
the	O
combination	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
and	O
IFN	B-GP
-	I-GP
γ	I-GP
could	O
not	O
completely	O
mimic	O
the	O
microenvironment	O
formed	O
by	O
M1	O
macrophages	O
.	O

The	O
key	O
factor	O
of	O
this	O
tumor	B-DS
promoting	O
pathway	O
is	O
the	O
MSCs	O
.	O

Recently	O
,	O
the	O
immune	O
modulatory	O
property	O
of	O
the	O
MSCs	O
has	O
been	O
extensively	O
studied	O
by	O
investigators	O
[	O
12	O
].	O

The	O
MSCs	O
influenced	O
both	O
adaptive	O
and	O
innate	O
immune	O
responses	O
.	O

The	O
ability	O
of	O
the	O
MSCs	O
to	O
control	O
an	O
inflammatory	O
environment	O
has	O
been	O
used	O
in	O
inflammatory	O
associated	O
disease	O
,	O
including	O
myocardial	B-DS
infarction	I-DS
[	O
19	O
],	O
peritonitis	B-DS
[	O
20	O
],	O
and	O
sepsis	B-DS
[	O
21	O
].	O

In	O
addition	O
to	O
polarization	O
of	O
macrophages	O
,	O
the	O
MSCs	O
could	O
also	O
polarize	O
into	O
two	O
distinctly	O
acting	O
phenotypes	O
following	O
specific	O
TLR	B-GP
-	O
activation	O
including	O
MSC1	B-GP
and	O
MSC2	B-GP
[	O
17	O
,	O
22	O
].	O

MSC1	B-GP
was	O
pro	O
-	O
inflammatory	O
,	O
and	O
MSC2	B-GP
showed	O
anti	O
-	O
inflammatory	O
properties	O
.	O

MSC1	B-GP
-	O
based	O
treatment	O
of	O
established	O
tumors	B-DS
in	O
an	O
immune	O
competent	O
model	O
attenuated	O
tumor	B-DS
growth	O
and	O
metastasis	O
in	O
contrast	O
to	O
MSC	O
-	O
or	O
MSC2	B-GP
-	O
treated	O
animals	B-OG
in	O
which	O
tumor	B-DS
growth	O
and	O
spread	O
was	O
increased	O
[	O
23	O
].	O

In	O
our	O
experiments	O
,	O
we	O
found	O
that	O
the	O
cMSCs	O
could	O
significantly	O
promote	O
tumor	B-DS
growth	O
,	O
recruit	O
CD45	B-GP
positive	O
bone	O
marrow	O
cells	O
in	O
vivo	O
,	O
and	O
had	O
immunosuppressive	O
potential	O
.	O

Meanwhile	O
,	O
Quantitative	O
PCR	O
showed	O
that	O
the	O
transcript	O
levels	O
of	O
iNOS	B-GP
and	O
TLR3	B-GP
were	O
markedly	O
higher	O
in	O
the	O
cMSCs	O
than	O
in	O
the	O
untreated	O
MSCs	O
.	O

Overall	O
,	O
these	O
results	O
may	O
suggest	O
that	O
the	O
cMSCs	O
had	O
a	O
regulatory	O
-	O
like	O
profile	O
similar	O
to	O
MSC2	B-GP
.	O

Previous	O
reports	O
indicated	O
that	O
the	O
MSCs	O
may	O
be	O
involved	O
in	O
cancer	B-DS
initiation	O
in	O
vivo	O
and	O
the	O
MSCs	O
may	O
spontaneously	O
transform	O
into	O
malignant	O
cells	O
in	O
vitro	O
[	O
24	O
].	O

It	O
is	O
clear	O
that	O
the	O
MSCs	O
secrete	O
a	O
number	O
of	O
paracrine	O
factors	O
that	O
may	O
influence	O
tumor	B-DS
growth	O
[	O
25	O
,	O
26	O
].	O

However	O
,	O
the	O
exact	O
mechanisms	O
of	O
MSCs	O
-	O
mediated	O
tumor	B-DS
growth	O
are	O
still	O
debated	O
,	O
especially	O
with	O
regards	O
to	O
immunosuppression	O
.	O

Previous	O
data	O
found	O
that	O
the	O
prevention	O
of	O
graft	B-DS
-	I-DS
versus	I-DS
-	I-DS
host	I-DS
disease	I-DS
by	O
the	O
MSCs	O
was	O
dependent	O
on	O
iNOS	B-GP
,	O
and	O
that	O
bone	O
marrow	O
-	O
derived	O
MSCs	O
could	O
exert	O
immunosuppressive	O
effects	O
by	O
iNOS	B-GP
to	O
favor	O
B16	O
melanoma	B-DS
cell	O
growth	O
[	O
18	O
].	O

In	O
our	O
experiments	O
,	O
cMSCs	O
-	O
mediated	O
immune	O
regulatory	O
effects	O
occurred	O
via	O
iNOS	B-GP
in	O
vitro	O
.	O

After	O
iNOS	B-GP
gene	O
knockdown	O
,	O
the	O
immune	O
suppression	O
and	O
tumor	B-DS
growth	O
enhancement	O
of	O
the	O
cMSCs	O
were	O
reduced	O
.	O

These	O
results	O
suggested	O
that	O
NO	O
-	O
mediated	O
immunosuppression	O
by	O
the	O
cMSCs	O
was	O
required	O
in	O
tumor	B-DS
progression	O
.	O

Additionally	O
,	O
macrophages	O
are	O
the	O
main	O
cells	O
in	O
the	O
tumor	B-DS
microenvironment	O
[	O
27	O
].	O

A	O
previous	O
study	O
showed	O
that	O
tumor	B-DS
-	O
educated	O
mesenchymal	O
stromal	O
cells	O
recruit	O
macrophages	O
via	O
CCR2	B-GP
[	O
15	O
].	O

In	O
our	O
experiments	O
,	O
we	O
found	O
that	O
the	O
cMSCs	O
could	O
recruit	O
macrophages	O
to	O
tumor	B-DS
sites	O
,	O
render	O
macrophages	O
into	O
M2	O
-	O
like	O
cells	O
,	O
and	O
consequently	O
enhance	O
tumor	B-DS
growth	O
.	O

Therefore	O
,	O
the	O
cMSCs	O
could	O
create	O
a	O
negative	O
-	O
feedback	O
loop	O
with	O
macrophages	O
in	O
the	O
tumor	B-DS
microenvironment	O
.	O

With	O
the	O
presence	O
of	O
pathogens	O
or	O
tissue	O
damage	O
,	O
the	O
negative	O
-	O
feedback	O
loop	O
may	O
be	O
initiated	O
by	O
tumor	B-DS
cells	O
following	O
accelerated	O
growth	O
.	O

In	O
the	O
tumor	B-DS
microenvironment	O
,	O
the	O
expression	O
of	O
various	O
immune	O
mediators	O
and	O
modulators	O
as	O
well	O
as	O
the	O
abundance	O
and	O
activation	O
state	O
of	O
different	O
cell	O
types	O
dictate	O
in	O
which	O
direction	O
the	O
balance	O
is	O
tipped	O
and	O
whether	O
tumor	B-DS
-	O
promoting	O
inflammation	O
or	O
antitumor	O
immunity	O
will	O
ensue	O
.	O

In	O
our	O
experiments	O
,	O
when	O
exposed	O
to	O
sufficient	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	B-GP
in	O
the	O
M1	O
medium	O
,	O
the	O
MSCs	O
responded	O
to	O
adopting	O
an	O
immune	O
regulatory	O
phenotype	O
to	O
dampen	O
inflammation	O
and	O
promote	O
tumor	B-DS
growth	O
.	O

Our	O
research	O
may	O
inspire	O
a	O
subsequent	O
study	O
especially	O
in	O
how	O
inflammation	O
induces	O
tumor	B-DS
development	O
.	O

MATERIALS	O
AND	O
METHODS	O

Reagents	O

Recombinant	O
mouse	B-OG
TNFα	B-GP
,	O
interferon	B-GP
(	O
IFNγ	B-GP
),	O
granulocyte	B-GP
macrophage	I-GP
-	I-GP
colony	I-GP
stimulating	I-GP
factor	I-GP
(	O
GM	B-GP
-	I-GP
CSF	I-GP
),	O
M	B-GP
-	I-GP
CSF	I-GP
,	O
interleukin	B-GP
(	I-GP
IL	I-GP
)-	I-GP
4	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
10	I-GP
,	O
IL	B-GP
-	I-GP
12	I-GP
,	O
IL	B-GP
-	I-GP
2	I-GP
and	O
IL	B-GP
-	I-GP
15	I-GP
were	O
from	O
Pepro	O
Tech	O
(	O
London	O
,	O
UK	O
).	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
was	O
purchased	O
from	O
Sigma	O
.	O

Monoclonal	O
rat	B-OG
anti	O
-	O
mouse	B-OG
antibodies	O
against	O
CD29	B-GP
,	O
CD44	B-GP
,	O
CD45	B-GP
,	O
and	O
CD11b	B-GP
were	O
from	O
BD	O
Biosciences	O
;	O
and	O
rabbit	B-OG
anti	O
-	O
mouse	B-OG
inducible	O
nitric	B-GP
oxide	I-GP
synthase	I-GP
(	O
iNOS	B-GP
)	O
and	O
CD206	B-GP
monoclonal	O
antibodies	O
were	O
from	O
Abcam	O
.	O

Alexa	O
Fluor	O
594	O
and	O
Alexa	O
Fluor	O
488	O
-	O
conjugated	O
secondary	O
antibodies	O
were	O
from	O
Invitrogen	O
.	O

Cell	O
culture	O

The	O
human	B-OG
breast	B-DS
carcinoma	I-DS
MDA	O
-	O
MB	O
-	O
231	O
-	O
FLUC	O
cells	O
,	O
human	B-OG
HCC	O
-	O
LM3	O
-	O
FLUC	O
hepatoma	B-DS
cells	O
,	O
human	B-OG
U87MG	O
-	O
FLUC	O
glioma	B-DS
cells	O
and	O
murine	B-OG
4T1	O
-	O
FLUC	O
breast	B-DS
cancer	I-DS
cells	O
were	O
stably	O
transfected	O
with	O
a	O
lentiviral	O
vector	O
containing	O
a	O
firefly	B-OG
luciferase	B-GP
reporter	O
gene	O
were	O
first	O
selected	O
in	O
vitro	O
,	O
and	O
then	O
injected	O
into	O
immune	O
-	O
deficient	O
or	O
normal	O
mice	B-OG
.	O

Murine	B-OG
macrophage	O
-	O
like	O
cells	O
RAW264	O
.	O
7	O
were	O
cultured	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
’	O
medium	O
(	O
Gibco	O
),	O
M1	O
-	O
polarized	O
macrophages	O
were	O
prepared	O
by	O
stimulating	O
RAW264	O
.	O
7	O
macrophages	O
with	O
100	O
IU	O
/	O
ml	O
IFNγ	B-GP
plus	O
10	O
ng	O
/	O
ml	O
LPS	O
overnight	O
.	O

MSCs	O
were	O
collected	O
from	O
the	O
bone	O
marrow	O
of	O
the	O
tibia	O
and	O
femurs	O
of	O
mice	B-OG
aged	O
6	O
–	O
10	O
weeks	O
.	O

Animal	B-OG
model	O

Female	O
C57BL	B-OG
/	I-OG
6	I-OG
nude	I-OG
mice	I-OG
(	O
6	O
–	O
7	O
weeks	O
old	O
)	O
were	O
purchased	O
from	O
the	O
Department	O
of	O
Experimental	O
Animals	B-OG
,	O
Peking	O
University	O
Health	O
Science	O
Center	O
.	O

Animal	B-OG
experiments	O
were	O
performed	O
according	O
to	O
the	O
guidelines	O
of	O
the	O
Institutional	O
Animal	B-OG
Care	O
and	O
Use	O
Committee	O
at	O
Peking	O
University	O
(	O
Permit	O
Number	O
:	O
2011	O
-	O
0039	O
).	O

Mice	B-OG
were	O
housed	O
in	O
a	O
specific	O
pathogen	O
-	O
free	O
colony	O
in	O
the	O
animal	B-OG
facility	O
,	O
and	O
100	O
μl	O
of	O
2	O
×	O
106	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
FLUC	O
cells	O
,	O
or	O
100	O
μl	O
of	O
2	O
×	O
106	O
4T1	O
-	O
FLUC	O
cells	O
suspended	O
in	O
saline	O
were	O
injected	O
into	O
the	O
mammary	O
glands	O
of	O
mice	B-OG
to	O
establish	O
the	O
orthotopic	O
breast	B-DS
cancer	I-DS
model	O
respectively	O
.	O

The	O
orthotopic	O
liver	O
mouse	B-OG
models	O
were	O
established	O
by	O
injecting	O
100	O
μl	O
of	O
2	O
×	O
106	O
HCC	O
-	O
LM3	O
-	O
FLUC	O
cells	O
suspended	O
in	O
saline	O
into	O
the	O
liver	O
of	O
BALB	B-OG
/	I-OG
c	I-OG
nude	I-OG
mice	I-OG
.	O

For	O
orthotopic	O
brain	B-DS
tumor	I-DS
models	O
,	O
10	O
μl	O
of	O
2	O
×	O
105	O
U87MG	O
-	O
FLUC	O
cells	O
suspended	O
in	O
saline	O
were	O
implanted	O
manually	O
2	O
mm	O
anterior	O
and	O
2	O
mm	O
to	O
the	O
right	O
of	O
the	O
bregma	O
in	O
the	O
brains	O
of	O
mice	B-OG
.	O

After	O
the	O
injection	O
,	O
the	O
surface	O
was	O
cleaned	O
with	O
a	O
sterile	O
cotton	O
swab	O
,	O
and	O
the	O
burr	O
hole	O
was	O
filled	O
with	O
bone	O
wax	O
.	O

To	O
detect	O
the	O
effect	O
of	O
the	O
cMSCs	O
on	O
tumor	B-DS
growth	O
,	O
breast	O
,	O
liver	O
,	O
and	O
brain	B-DS
carcinoma	I-DS
cells	O
were	O
injected	O
either	O
alone	O
or	O
coupled	O
with	O
the	O
MSCs	O
into	O
nude	B-OG
mice	I-OG
.	O

The	O
MSCs	O
were	O
treated	O
with	O
M1	O
medium	O
or	O
left	O
untreated	O
.	O

Tumor	B-DS
cell	O
growth	O
was	O
evaluated	O
by	O
BLI	O
.	O

Mice	B-OG
were	O
divided	O
into	O
three	O
groups	O
(	O
n	O
=	O
6	O
per	O
group	O
):	O
the	O
MSCs	O
group	O
,	O
in	O
which	O
mice	B-OG
received	O
co	O
-	O
injection	O
of	O
1	O
×	O
106	O
MSCs	O
and	O
tumor	B-DS
cells	O
in	O
PBS	O
;	O
the	O
cMSCs	O
group	O
,	O
in	O
which	O
mice	B-OG
received	O
the	O
same	O
amount	O
of	O
M1	O
medium	O
-	O
treated	O
MSCs	O
and	O
cancer	B-DS
cells	O
;	O
and	O
the	O
control	O
(	O
PBS	O
)	O
group	O
received	O
only	O
PBS	O
and	O
cancer	B-DS
cells	O
.	O

Mice	B-OG
were	O
matched	O
for	O
age	O
and	O
gender	O
in	O
each	O
experiment	O
.	O

To	O
determine	O
the	O
effect	O
of	O
iNOS	B-GP
in	O
the	O
cMSCs	O
,	O
4T1	O
-	O
FLUC	O
tumor	B-DS
cell	O
growth	O
was	O
detected	O
by	O
BLI	O
after	O
establishing	O
the	O
breast	B-DS
carcinoma	I-DS
model	O
.	O

Animals	B-OG
were	O
divided	O
into	O
two	O
groups	O
(	O
n	O
=	O
6	O
per	O
group	O
):	O
the	O
si	O
-	O
iNOS	B-GP
/	O
cMSCs	O
group	O
,	O
in	O
which	O
mice	B-OG
received	O
1	O
×	O
106	O
iNOS	B-GP
siRNA	O
treated	O
cMSCs	O
and	O
2	O
×	O
106	O
4T1	O
-	O
FLUC	O
cells	O
in	O
100	O
μl	O
of	O
PBS	O
;	O
and	O
the	O
control	O
(	O
si	O
-	O
control	O
/	O
cMSCs	O
)	O
group	O
also	O
received	O
1	O
×	O
106	O
control	O
siRNA	O
treated	O
cMSCs	O
and	O
2	O
×	O
106	O
tumor	B-DS
cells	O
in	O
100	O
μl	O
of	O
PBS	O
.	O

Mice	B-OG
were	O
matched	O
for	O
age	O
and	O
gender	O
in	O
each	O
experiment	O
.	O

To	O
examine	O
the	O
effect	O
of	O
macrophages	O
on	O
tumor	B-DS
growth	O
in	O
vivo	O
,	O
mice	B-OG
were	O
injected	O
with	O
approximately	O
110	O
mg	O
/	O
kg	O
of	O
clodronate	O
liposomes	O
I	O
.	O
P	O
.	O
or	O
equal	O
volume	O
of	O
PBS	O
liposomes	O
.	O

Then	O
,	O
1	O
×	O
106	O
MSCs	O
or	O
cMSCs	O
were	O
co	O
-	O
injected	O
with	O
4T1	O
-	O
FLUC	O
cells	O
.	O

Tumor	B-DS
cell	O
growth	O
was	O
evaluated	O
by	O
BLI	O
on	O
day	O
14	O
.	O

To	O
determine	O
the	O
effect	O
of	O
MCP1	B-GP
on	O
cMSCs	O
,	O
cMSCs	O
were	O
transfected	O
with	O
MCP1	B-GP
siRNA	O
.	O

Animals	B-OG
were	O
divided	O
into	O
two	O
groups	O
(	O
n	O
=	O
6	O
per	O
group	O
):	O
the	O
si	O
-	O
MCP1	B-GP
/	O
cMSCs	O
group	O
,	O
in	O
which	O
mice	B-OG
received	O
1	O
×	O
106	O
MCP1	B-GP
siRNA	O
treated	O
cMSCs	O
and	O
2	O
×	O
106	O
4T1	O
-	O
FLUC	O
cells	O
in	O
100	O
μl	O
of	O
PBS	O
;	O
and	O
the	O
control	O
(	O
si	O
-	O
control	O
/	O
cMSCs	O
)	O
group	O
also	O
received	O
1	O
×	O
106	O
control	O
siRNA	O
treated	O
cMSCs	O
and	O
2	O
×	O
106	O
tumor	B-DS
cells	O
in	O
100	O
μl	O
of	O
PBS	O
.	O

Mice	B-OG
were	O
matched	O
for	O
age	O
and	O
gender	O
in	O
each	O
experiment	O
.	O

To	O
examine	O
the	O
effect	O
of	O
the	O
cMSCs	O
educated	O
macrophages	O
on	O
tumor	B-DS
growth	O
,	O
cMSCs	O
educated	O
macrophages	O
were	O
co	O
-	O
injected	O
with	O
4T1	O
-	O
FLUC	O
cells	O
,	O
and	O
tumor	B-DS
cell	O
growth	O
was	O
evaluated	O
by	O
BLI	O
.	O

BLI	O

BLI	O
was	O
performed	O
using	O
the	O
Xenogen	O
IVIS	O
Lumina	O
II	O
system	O
(	O
Perkin	O
Elmer	O
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
as	O
detailed	O
previously	O
[	O
28	O
,	O
29	O
].	O

Real	O
-	O
time	O
PCR	O

Total	O
RNA	O
was	O
extracted	O
from	O
cell	O
pellets	O
using	O
Trizol	O
Reagent	O
(	O
Invitrogen	O
)	O
and	O
treated	O
with	O
RNase	B-GP
-	O
free	O
DNase	B-GP
I	I-GP
(	O
Qiagen	O
,	O
USA	O
).	O

First	O
-	O
strand	O
cDNA	O
synthesis	O
was	O
performed	O
using	O
an	O
ABI	O
High	O
-	O
Capacity	O
cDNA	O
RT	O
kit	O
(	O
Applied	O
Biosystems	O
,	O
USA	O
).	O

Then	O
,	O
RT	O
-	O
PCR	O
and	O
Real	O
-	O
time	O
PCR	O
were	O
done	O
.	O

Primers	O
used	O
in	O
PCR	O
are	O
listed	O
in	O
Table	O
S1	O
,	O
including	O
interleukin	B-GP
-	I-GP
6	I-GP
(	O
IL	B-GP
-	I-GP
6	I-GP
),	O
monocyte	B-GP
chemoattractant	I-GP
protein	I-GP
(	O
MCP1	B-GP
),	O
Macrophage	B-GP
inflammatory	I-GP
protein	I-GP
-	I-GP
1β	I-GP
(	O
MIP	B-GP
-	I-GP
1β	I-GP
),	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
-	I-GP
α	I-GP
(	O
TNF	B-GP
-	I-GP
α	I-GP
),	O
interleukin	B-GP
-	I-GP
19	I-GP
(	O
IL	B-GP
-	I-GP
19	I-GP
),	O
matrix	B-GP
metalloproteinase	I-GP
-	I-GP
2	I-GP
(	O
MMP	B-GP
-	I-GP
2	I-GP
),	O
arginase	B-GP
type	I-GP
1	I-GP
(	O
Arg	B-GP
-	I-GP
1	I-GP
),	O
inflammatory	B-GP
zone	I-GP
1	I-GP
(	O
FIZZ	B-GP
-	I-GP
1	I-GP
),	O
interleukin	B-GP
-	I-GP
10	I-GP
(	O
IL	B-GP
-	I-GP
10	I-GP
),	O
CD47	B-GP
,	O
and	O
signal	B-GP
regulatory	I-GP
protein	I-GP
alpha	I-GP
(	O
SIRPα	B-GP
).	O

The	O
total	O
amount	O
of	O
mRNA	O
was	O
normalized	O
to	O
endogenous	O
GAPDH	B-GP
mRNA	O
.	O

Real	O
-	O
time	O
PCR	O
was	O
performed	O
in	O
triplicate	O
with	O
the	O
Fast	O
Start	O
Universal	O
SYBR	O
Green	O
Master	O
(	O
ROX	O
;	O
Roche	O
,	O
Mannheim	O
,	O
Germany	O
)	O
and	O
the	O
iCycler	O
iQ52	O
.	O
0	O
Standard	O
Edition	O
Optical	O
System	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
).	O

To	O
assess	O
the	O
gene	O
expression	O
of	O
the	O
cMSCs	O
,	O
the	O
MSCs	O
were	O
seeded	O
onto	O
12	O
-	O
well	O
plates	O
(	O
Corning	O
,	O
USA	O
)	O
at	O
a	O
density	O
of	O
2	O
×	O
105	O
cells	O
/	O
well	O
and	O
incubated	O
overnight	O
.	O

The	O
medium	O
was	O
replaced	O
with	O
a	O
fresh	O
M1	O
medium	O
and	O
cultured	O
for	O
24	O
h	O
,	O
after	O
which	O
real	O
-	O
time	O
PCR	O
analysis	O
was	O
performed	O
.	O

All	O
experiments	O
were	O
performed	O
in	O
triplicate	O
.	O

To	O
examine	O
the	O
gene	O
expression	O
of	O
the	O
cMSCs	O
educated	O
macrophages	O
,	O
RAW264	O
.	O
7	O
macrophages	O
were	O
co	O
-	O
cultured	O
with	O
cMSCs	O
in	O
a	O
transwell	O
for	O
24	O
hours	O
.	O

The	O
upper	O
part	O
was	O
the	O
MSCs	O
,	O
and	O
the	O
lower	O
portion	O
included	O
macrophages	O
.	O

Then	O
,	O
real	O
-	O
time	O
PCR	O
analysis	O
was	O
performed	O
.	O

All	O
experiments	O
were	O
performed	O
in	O
triplicate	O
.	O

Immunohistochemistry	O

Tumors	B-DS
were	O
washed	O
thoroughly	O
in	O
PBS	O
and	O
embedded	O
in	O
the	O
optimal	O
cutting	O
temperature	O
medium	O
(	O
OCT	O
)	O
(	O
Sakura	O
Finetek	O
,	O
Torrance	O
,	O
CA	O
,	O
USA	O
).	O

Cryosections	O
(	O
5	O
–	O
6	O
μm	O
)	O
were	O
cut	O
and	O
stained	O
with	O
antibodies	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

To	O
quantify	O
tumor	B-DS
-	O
associated	O
bone	O
marrow	O
cell	O
recruitment	O
,	O
the	O
tumor	B-DS
sections	O
were	O
stained	O
with	O
rat	B-OG
anti	O
-	O
mouse	B-OG
CD45	B-GP
(	O
BD	O
Biosciences	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
),	O
and	O
the	O
percentage	O
of	O
CD45	B-GP
-	O
positive	O
cells	O
was	O
determined	O
by	O
counting	O
the	O
number	O
of	O
cells	O
in	O
six	O
random	O
fields	O
(	O
400	O
×	O
magnification	O
)	O
from	O
three	O
histology	O
sections	O
.	O

Counting	O
was	O
performed	O
by	O
two	O
“	O
blinded	O
”	O
independent	O
investigators	O
.	O

Alexa	O
Fluor	O
594	O
-	O
conjugated	O
donkey	B-OG
anti	O
-	O
rat	B-OG
secondary	O
antibody	O
(	O
BD	O
Biosciences	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
was	O
applied	O
appropriately	O
.	O

DAPI	O
was	O
used	O
for	O
nuclear	O
counterstaining	O
.	O

Short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
synthesis	O
and	O
transient	O
transfection	O

The	O
siRNA	O
sequences	O
of	O
iNOS	B-GP
(	O
Sense	O
:	O
5	O
′-	O
CAGCTGGGCTGTACAAACCdTdT	O
-	O
3	O
;	O
Antisense	O
:	O
5	O
′-	O
CATTGGAAGTGAAGCGTTTCGdTdT	O
-	O
3	O
′)	O
and	O
MCP1	B-GP
(	O
Sense	O
:	O
5	O
′-	O
AAUUGAUUUAGCGUACACGdTdT	O
-	O
3	O
;	O
Antisense	O
:	O
5	O
′-	O
CGUGUACGCUAAAUCAAUUdTdT	O
-	O
3	O
′)	O
were	O
designed	O
by	O
using	O
Oligoengine	O
software	O
and	O
confirmed	O
by	O
the	O
nucleotide	O
Basic	O
Local	O
Alignment	O
Search	O
Tool	O
(	O
BLAST	O
)	O
searches	O
.	O

Transfections	O
were	O
performed	O
with	O
a	O
Lipofectamine	O
2000	O
kit	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Cells	O
(	O
1	O
–	O
3	O
×	O
106	O
)	O
grown	O
to	O
a	O
confluency	O
of	O
50	O
–	O
60	O
%	O
in	O
10	O
cm	O
Petri	O
dishes	O
were	O
transfected	O
with	O
the	O
siRNA	O
sequence	O
,	O
and	O
then	O
the	O
cells	O
were	O
harvested	O
48	O
hours	O
after	O
transfection	O
.	O

Flow	O
cytometry	O

For	O
macrophage	O
surface	O
marker	O
analysis	O
,	O
macrophages	O
were	O
incubated	O
with	O
fluorescent	O
labeled	O
rat	B-OG
anti	O
-	O
mouse	B-OG
CD11b	B-GP
,	O
iNOS	B-GP
,	O
and	O
CD206	B-GP
antibodies	O
(	O
BD	O
Biosciences	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
).	O

To	O
measure	O
macrophage	O
infiltration	O
in	O
the	O
tumor	B-DS
sites	O
and	O
blood	O
,	O
the	O
tumor	B-DS
cells	O
and	O
peripheral	O
cells	O
were	O
stained	O
with	O
Alexa	O
Fluor	O
®	O
594	O
-	O
conjugated	O
rabbit	B-OG
anti	O
-	O
mouse	B-OG
CD206	B-GP
(	O
Abcam	O
,	O
Cambridge	O
,	O
MA	O
)	O
and	O
FITC	O
-	O
labeled	O
anti	O
-	O
mouse	B-OG
F4	O
/	O
80	O
(	O
Abcam	O
,	O
Cambridge	O
,	O
MA	O
).	O

Statistical	O
analysis	O

All	O
data	O
were	O
expressed	O
as	O
the	O
mean	O
±	O
SEM	O
.	O

One	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
was	O
used	O
to	O
determine	O
the	O
intergroup	O
differences	O
.	O

Least	O
significant	O
difference	O
(	O
equal	O
variances	O
)	O
and	O
Dunnett	O
'	O
s	O
T3	O
(	O
non	O
-	O
equal	O
variances	O
)	O
post	O
hoc	O
tests	O
were	O
used	O
for	O
testing	O
the	O
differences	O
between	O
groups	O
.	O

All	O
tests	O
were	O
two	O
-	O
tailed	O
,	O
and	O
differences	O
were	O
considered	O
statistically	O
significant	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O

SUPPLEMENTARY	O
MATERIALS	O
FIGURES	O
AND	O
TABLE	O

CONFLICTS	O
OF	O
INTEREST	O

The	O
authors	O
declare	O
no	O
conflicts	O
of	O
interests	O
.	O

